Regulator of G protein signaling (RGS) proteins negatively regulate receptor-mediated second messenger responses by enhancing the GTPase activity of G␣ subunits. We describe a receptor-specific role for an RGS protein at the level of an individual brain neuron. RGS9-2 and G␤5 mRNA and protein complexes were detected in striatal cholinergic and ␥-aminobutyric acidergic neurons. Dialysis of cholinergic neurons with RGS9 constructs enhanced basal Ca 2؉ channel currents and reduced D2 dopamine receptor modulation of Cav2.2 channels. These constructs did not alter M2 muscarinic receptor modulation of Cav2.2 currents in the same neuron. The noncatalytic DEP-GGL domain of RGS9 antagonized endogenous RGS9-2 activity, enhancing D2 receptor modulation of Ca 2؉ currents. In vitro, RGS9 constructs accelerated GTPase activity, in agreement with electrophysiological measurements, and did so more effectively at Go than Gi. These results implicate RGS9-2 as a specific regulator of dopamine receptor-mediated signaling in the striatum and identify a role for GAP activity modulation by the DEP-GGL domain.calcium ͉ GTPase activating protein ͉ receptor-specific ͉ basal ganglia ͉ indirect pathway R egulators of G protein signaling (RGS) are a diverse family of proteins identified by the presence of a 120-aa domain termed the RGS box. In cell lines or in purified in vitro assays, most RGS proteins enhance the GTPase activity of heterotrimeric G protein ␣ subunits and thereby accelerate the deactivation of receptor-initiated second messenger responses. Many RGS proteins also contain one or more putative protein-protein interaction domains. These noncatalytic domains have been suggested to regulate catalytic activity, signal transduction pathway specificity, and͞or subcellular targeting of RGS proteins.One subfamily of RGS proteins (RGS6, -7, -9, and -11) all share homologous DEP (Dishevelled, Egl-10, Pleckstrin), GGL (G protein Gamma subunit Like), and RGS domains. The DEP domain of the retinal isoform of RGS9 (RGS9-1) has been shown to confer localization to a retinal membrane protein termed R9AP, and this localization has been shown to be necessary for proper RGS9-1 function in the retina (1). Several investigators have demonstrated that the GGL domain interacts with the G␤ 5 subunit (2-6). In vitro, G␤ 5 binding to RGS6, -7, or -11 increases the GAP specificity of these RGS proteins for G␣ (2, 3). In addition, G␤ 5 binding to either RGS7 or RGS9 enhances RGS-mediated acceleration of G protein gated inwardly rectifying K ϩ (Kir3) channel activation and deactivation kinetics in an oocyte expression system. This enhancement may result from G␤ 5 -mediated increased stability of the RGS protein or enhanced GAP activity (7).Despite the functional similarities among RGS6, -7, -9, and -11 in heterologous expression systems or when analyzed in vitro, each of these RGS proteins is likely to play a unique role in the central nervous system because they are differentially localized within the brain (8, 9). In contrast to the more ubiquitous loc...

Spanning over three decades of extensive drug discovery research, the efforts to develop a potent and selective GSK3 inhibitor as a therapeutic for the treatment of type 2 diabetes, Alzheimer's disease (AD), bipolar disorders and cancer have been futile. Since its initial discovery in 1980 and subsequent decades of research, one cannot underscore the importance of the target and the promise of a game changing disease modifier. Several pharmaceutical companies, biotech companies, and academic institutions raged in a quest to unravel the biology and discover potent and selective GSK3 inhibitors, some of which went through clinical trials. However, the conundrum of what happened to the fate of the AstraZeneca's GSK3 inhibitors and the undertaking to find a therapeutic that could control glycogen metabolism and aberrant tau hyperphosphorylation in the brain, and rescue synaptic dysfunction has largely been untold. AstraZeneca was in the forefront of GSK3 drug discovery research with six GSK3 drug candidates, one of which progressed up to Phase II clinical trials in the quest to untangle the tau hypothesis for AD. Analysis of key toxicity issues, serendipitous findings and efficacy, and biomarker considerations in relation to safety margins have limited the potential of small molecule therapeutics as a way forward. To guide future innovation of this important target, we reveal the roller coaster journey comprising of two decades of preclinical and clinical GSK3 drug discovery at AstraZeneca; the understanding of which could lead to improved GSK3 therapies for disease. These learnings in combination with advances in achieving kinase selectivity, different modes of action as well as the recent discovery of novel conjugated peptide technology targeting specific tissues have potentially provided a venue for scientific innovation and a new beginning for GSK3 drug discovery.

Bacterial lipopolypolysaccharide (LPS)-induced fever involves induction of the proinflammatory cytokines interleukin (IL)-1 alpha, IL-1 beta, tumor necrosis factor-alpha (TNF-alpha), and IL-6, both in the periphery and in the brain. These molecules can induce expression of each other and also regulate expression of their own receptors in a complex manner. The functional hierarchy of these highly inducible proteins is therefore difficult to determine. Using mice strains carrying the null mutations of IL-1 beta, IL-1RI, IL-1RAcP, or IL-6, respectively, we show that LPS-induced fever involves IL-1 beta, which acts at a complex consisting of the type I IL-1 receptor and the IL-1RAcP. This action occurs prior to central IL-6 release, which has been shown to be a necessary component of fever responses induced by LPS, IL-1 beta, and also TNF-alpha. In the absence of IL-1 beta, as in IL-1 beta-deficient mice, LPS, IL-1 alpha, and IL-1 beta cause hyperresponsive fevers when exogenously applied. Murine TNF-alpha is a poor pyrogen in mice even when mice are kept at thermoneutral temperature (30 degrees C). TNF-alpha-mediated fever depends on central IL-6 expression.

The interleukin-1 (IL-1) receptor antagonist (IL-1ra) is an endogenous antagonist that blocks the effects of the proinflammatory cytokines IL-1α and IL-1β by occupying the type I IL-1 receptor. Here we describe transgenic mice with astrocyte-directed overexpression of the human secreted IL-1ra (hsIL-1ra) under the control of the murine glial fibrillary acidic protein (GFAP) promoter. Two GFAP-hsIL-1ra strains have been generated and characterized further: GILRA2 and GILRA4. These strains show a brain-specific expression of the hsIL-1ra at the mRNA and protein levels. The hsIL-1ra protein was approximated to ∼50 ng/brain in cytosolic fractions of whole brain homogenates, with no differences between male and female mice or between the two strains. Furthermore, the protein is secreted, inasmuch as the concentration of hsIL-1ra in the cerebrospinal fluid was 13 (GILRA2) to 28 (GILRA4) times higher in the transgenic mice than in the control animals. To characterize the transgenic phenotype, GILRA mice and nontransgenic controls were injected with recombinant human IL-1β (central injection) or lipopolysaccharide (LPS, peripheral injection). The febrile response elicited by IL-1β (50 ng/mouse icv) was abolished in hsIL-1ra-overexpressing animals, suggesting that the central IL-1 receptors were occupied by antagonist. The peripheral LPS injection (25 μg/kg ip) triggered a fever in overexpressing and control animals. Moreover, no differences were found in LPS-induced (100 and 1,000 μg/kg ip; 1 and 6 h after injection) IL-1β and IL-6 serum levels between GILRA and wild-type mice. On the basis of these results, we suggest that binding of central IL-1 to central IL-1 receptors is not important in LPS-induced fever or LPS-induced IL-1β and IL-6 plasma levels.